The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived differences, according to Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine.
The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived differences—especially because of the rigorous examination they received before FDA approval, according to Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine.
Transcript (slightly modified)
Why do you think some physicians are hesitant about substituting their patients’ treatment with a biosimilar and how can we overcome that barrier?
I believe it may be related to the same hesitation to using a generic drug, that I think they perceive that there could be differences. But in actuality, having just reviewed all of the details of the steps in the process that the first biosimilar went through—in terms of physical-chemical comparison, in terms of pharmacokinetics and pharmacodynamics, clinical trial comparison—and seeing just exactly how exacting that proof was, I believe that there shouldn’t be hesitation. The bar is set very high in terms of how similar is required in order to meet that biosimilar requirement definition.
Is there a need for patient education on biosimilars?
I think there’ll be the same hesitation on having a biosimilar in terms of the concern that it’s less effective in some way or that there’ll be other side effects. But the side effect profiles and the efficacy have to be proven before the FDA will consider that approval. So in some ways I feel like the regulation is so strict that I don’t anticipate that there’ll be new problems.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More